Skip to main content
CYTK logo

CYTK · Cytokinetics Inc · Webcasts, Transcripts & Audio

Track CYTK — free
Market Cap
$7.20B
Shares
139.30M
Volume · Nov 17 2.71M Avg daily vol (3M) 2.01M

Cytokinetics Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Cytokinetics Inc (CYTK), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-30
Cytokinetics Inc (CYTK) November 30, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-17
Cytokinetics Inc (CYTK) November 17, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-16
Cytokinetics Inc (CYTK) November 16, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-10
Cytokinetics Inc (CYTK) November 10, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-04
Cytokinetics Inc (CYTK) Q3 2026 Earnings Call Transcript
Confident tone Mycorso U.S. commercial launch Acacia HCM and potential NHCM launch International expansion
Revenue
$47.56M
▲ 2356.5% YoY
Diluted EPS
$-1.37
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-14
Cytokinetics Inc (CYTK) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Cytokinetics Inc (CYTK) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Cytokinetics Inc (CYTK) Q2 2026 Earnings Call Transcript
Confident tone Mycorso U.S. commercial launch momentum Aficampten NHCM label expansion (Acacia-HCM) Regulatory and FDA interactions (priority review)
Revenue
$28.62M
▼ 57.1% YoY
Diluted EPS
$-1.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Cytokinetics Inc (CYTK) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Cytokinetics Inc (CYTK) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-19
Cytokinetics Inc (CYTK) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Cytokinetics Inc (CYTK) Q1 2026 Earnings Call Transcript
Confident tone Acacia HCM Phase 3 results MYCorzo U.S. commercial launch Financial performance and guidance
Revenue
$19.36M
▲ 1125.8% YoY
Diluted EPS
$-1.67
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-13
Cytokinetics Inc (CYTK) April 13, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-03-11
Cytokinetics Inc (CYTK) March 11, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-24
Cytokinetics Inc (CYTK) Q4 2025 Earnings Call Transcript
Confident tone MYCorzo U.S. commercial launch Regulatory approvals and global expansion ACACIA-HCM in non-obstructive HCM
Revenue
$17.75M*
▲ 4.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Cytokinetics Inc (CYTK) Q3 2025 Earnings Call Transcript
Confident tone Pipeline programs beyond aficamten FDA approval and launch readiness for aficamten Nonobstructive HCM (nHCM) opportunity
Revenue
$1.94M
▲ 318.1% YoY
Diluted EPS
$-2.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Cytokinetics Inc (CYTK) Q2 2025 Earnings Call Transcript
Confident tone ACACIA-HCM in non-obstructive HCM Heart failure pipeline (omecamtiv mecarbil / ulacamten) FDA regulatory review of aficamten (PDUFA extension)
Revenue
$66.77M
▲ 26714.9% YoY
Diluted EPS
$-1.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Transcript
Positive tone Aficamten oHCM NDA approval FDA REMS and PDUFA extension ACACIA-HCM nHCM pivotal trial
Revenue
$1.58M
▲ 89.1% YoY
Diluted EPS
$-1.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Transcript
Confident tone Commercial readiness and U.S. launch International partnerships Pipeline diversification
Revenue
$16.93M*
▲ 912.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Date not confirmed
Cytokinetics Inc (CYTK) Q3 2024 Earnings Call Transcript
Confident tone Pipeline diversification beyond aficamten Aficamten NDA submission and FDA review Earlier-stage pipeline and neuromuscular programs
Revenue
$463,000
▲ 22.5% YoY
Diluted EPS
$-1.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Cytokinetics Inc (CYTK) Q2 2024 Earnings Call
Revenue
$249,000
▼ 71.3% YoY
Diluted EPS
$-1.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Cytokinetics Inc (CYTK) Q1 2024 Earnings Call Transcript
Confident tone Aficamten pivotal data and presentations Commercial readiness for launch Regulatory submissions and FDA engagement
Revenue
$835,000
▼ 81.9% YoY
Diluted EPS
$-1.33
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Cytokinetics Inc (CYTK) Q4 2023 Earnings Call Transcript
Confident tone SEQUOIA-HCM Phase 3 results Additional aficamten clinical trials Pipeline beyond aficamten
Revenue
$1.67M*
▼ 14.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Cytokinetics Inc (CYTK) Q3 2023 Earnings Call Transcript
Revenue
$378,000
▼ 85% YoY
Diluted EPS
$-1.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Cytokinetics Inc (CYTK) Q2 2023 Earnings Call Transcript
Revenue
$867,000
▼ 99% YoY
Diluted EPS
$-1.34
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Cytokinetics Inc (CYTK) Q1 2023 Earnings Call Transcript
Revenue
$4.61M
▲ 301.8% YoY
Diluted EPS
$-1.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Cytokinetics Inc (CYTK) Q4 2022 Earnings Call Transcript
Revenue
$1.96M*
▼ 96.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Cytokinetics Inc (CYTK) Q3 2022 Earnings Call Transcript
Revenue
$2.52M
▼ 53.7% YoY
Diluted EPS
$-1.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Cytokinetics Inc (CYTK) Q2 2022 Earnings Call Transcript
Revenue
$88.97M
▲ 3029.4% YoY
Diluted EPS
$-0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Cytokinetics Inc (CYTK) Q1 2022 Earnings Call Transcript
Revenue
$1.15M
▼ 82.5% YoY
Diluted EPS
$-1.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Cytokinetics Inc (CYTK) Q4 2021 Earnings Call Transcript
Revenue
$55.60M*
▲ 727.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Cytokinetics Inc (CYTK) Q3 2021 Earnings Call Transcript
Revenue
$5.44M
▼ 87% YoY
Diluted EPS
$-0.95
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Cytokinetics Inc (CYTK) Q2 2021 Earnings Call Transcript
Revenue
$2.84M
▼ 20.9% YoY
Diluted EPS
$-0.86
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Cytokinetics Inc (CYTK) Q1 2021 Earnings Call Transcript
Revenue
$6.55M
▲ 71.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Cytokinetics Inc (CYTK) Q4 2020 Earnings Call Transcript
Revenue
$6.72M*
▲ 29% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Cytokinetics Inc (CYTK) Q3 2020 Earnings Call Transcript
Revenue
$41.69M
▲ 588.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Cytokinetics Inc (CYTK) Q2 2020 Earnings Call Transcript
Revenue
$3.59M
▼ 49.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-14
Cytokinetics Inc (CYTK) Q1 2020 Earnings Call Transcript
Revenue
$3.83M
▼ 54.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–38 of 38 webcasts
Key facts CIK 1061983 CUSIP 23282W605 13F (30d) 489 filings 451 filers Visit website Investor relations